Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on March 18, 2026. The filing announces positive exploratory findings from a recently completed Phase 2 proof-of-concept trial of urcosimod (0.05%) for the treatment of Neuropathic Corneal Pain (NCP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements.
Material Changes
The primary material change is the completion of the Phase 2a clinical trial and the subsequent analysis of patient-reported outcomes. Key findings include:
- Clinically meaningful pain reduction measured by the Visual Analog Scale (VAS).
- Improvements in patient-reported quality-of-life (QoL) measures.
- Signals suggesting potential restoration of corneal nerve structure in NCP patients.
Guidance, Outlook, and Risks
Management plans to present these findings at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. The presentation is titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients." The filing does not provide specific financial guidance, risk factors, or contingencies beyond the standard disclaimer that the attached news announcement is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full text of the news announcement (Exhibit 99.1) for detailed statistical data on pain reduction and QoL improvements.
- Confirm the date and session details for the ARVO 2026 Annual Meeting presentation.
- Review the company's latest Form 20-F for current financial status, as this 6-K contains no financial data.
- Assess the regulatory pathway for urcosimod following these Phase 2a results.